Inoviq Ltd (ASX: IIQ) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Inoviq Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Inoviq Ltd (ASX: IIQ)
Latest News
Share Gainers
3 ASX biotech shares rocketing 10% to 26% on BIG news!
Healthcare Shares
What's going on with the Inoviq (ASX:IIQ) share price today?
Healthcare Shares
Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?
Share Gainers
BARD1 (ASX:BD1) share price ends stellar day up 41%
Healthcare Shares
BARD1 Life Sciences (ASX:BD1) share price leaps 16% on US patent news
Share Market News
BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update
Healthcare Shares
Here's why the BARD1 (ASX:BD1) share price is falling 7% today
Share Fallers
Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking
Capital Raising
BARD1 (ASX:BD1) share price falls 6% on placement update
Share Market News
Here's why the BARD1 (ASX:BD1) share price is frozen today
Healthcare Shares
Why the BARD1 (ASX:BD1) share price is surging 10% higher
Share Fallers
Why the BARD1 (ASX:BD1) share price plummeted 9% today
IIQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Inoviq Ltd
INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. Its activities include research and development of non-invasive diagnostic tests for early detection of cancer, based on certain proprietary intellectual property. The company was founded on June 30, 1983 and is headquartered in Subiaco, Australia.
IIQ Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
12 Dec 2024 | $0.53 | $0.01 | 1.90% | 164,943 | $0.53 | $0.55 | $0.53 |
11 Dec 2024 | $0.53 | $-0.01 | -1.87% | 103,918 | $0.54 | $0.54 | $0.52 |
10 Dec 2024 | $0.54 | $-0.01 | -1.85% | 182,586 | $0.55 | $0.55 | $0.51 |
09 Dec 2024 | $0.54 | $-0.02 | -3.54% | 291,104 | $0.57 | $0.58 | $0.54 |
06 Dec 2024 | $0.57 | $0.05 | 9.71% | 782,926 | $0.54 | $0.57 | $0.53 |
05 Dec 2024 | $0.52 | $0.02 | 4.00% | 712,789 | $0.51 | $0.56 | $0.51 |
04 Dec 2024 | $0.50 | $-0.02 | -3.88% | 118,876 | $0.53 | $0.53 | $0.50 |
03 Dec 2024 | $0.52 | $0.05 | 10.75% | 689,864 | $0.51 | $0.54 | $0.50 |
02 Dec 2024 | $0.47 | $0.01 | 2.17% | 31,540 | $0.46 | $0.47 | $0.45 |
29 Nov 2024 | $0.46 | $0.04 | 9.41% | 99,269 | $0.45 | $0.46 | $0.45 |
28 Nov 2024 | $0.43 | $-0.02 | -4.55% | 44,071 | $0.44 | $0.44 | $0.42 |
27 Nov 2024 | $0.44 | $0.02 | 4.71% | 41,196 | $0.42 | $0.44 | $0.42 |
26 Nov 2024 | $0.43 | $-0.02 | -4.55% | 140,758 | $0.44 | $0.44 | $0.43 |
25 Nov 2024 | $0.44 | $0.01 | 2.30% | 10,214 | $0.44 | $0.44 | $0.44 |
22 Nov 2024 | $0.44 | $-0.01 | -2.25% | 36,000 | $0.45 | $0.45 | $0.44 |
21 Nov 2024 | $0.45 | $-0.01 | -2.20% | 64,882 | $0.45 | $0.47 | $0.44 |
20 Nov 2024 | $0.46 | $-0.02 | -4.26% | 30,102 | $0.47 | $0.47 | $0.46 |
19 Nov 2024 | $0.47 | $-0.01 | -2.11% | 67,707 | $0.48 | $0.50 | $0.47 |
18 Nov 2024 | $0.48 | $0.04 | 9.09% | 77,577 | $0.44 | $0.48 | $0.44 |
15 Nov 2024 | $0.44 | $0.01 | 2.30% | 28,787 | $0.44 | $0.44 | $0.43 |
14 Nov 2024 | $0.44 | $-0.01 | -2.27% | 32,550 | $0.44 | $0.44 | $0.44 |
13 Nov 2024 | $0.44 | $-0.01 | -2.22% | 17,391 | $0.44 | $0.44 | $0.43 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
29 Nov 2024 | Philip (Phil) Powell | Issued | 250,000 | $115,000 |
Issue of options.
|
29 Nov 2024 | Geoffrey Cumming | Issued | 250,000 | $115,000 |
Issue of options.
|
29 Nov 2024 | Robert (Max) Johnston | Issued | 250,000 | $115,000 |
Issue of options.
|
29 Nov 2024 | Mary Harney | Issued | 250,000 | $115,000 |
Issue of options.
|
30 Sep 2024 | Robert (Max) Johnston | Expiry | 250,000 | $125,000 |
Options expired.
|
30 Sep 2024 | Philip (Phil) Powell | Expiry | 250,000 | $125,000 |
Options expired.
|
30 Sep 2024 | Geoffrey Cumming | Expiry | 250,000 | $125,000 |
Options expired.
|
28 Aug 2024 | Geoffrey Cumming | Issued | 60,000 | $30,000 |
Placement.
|
28 Aug 2024 | Geoffrey Cumming | Issued | 30,000 | $17,100 |
Placement. As per announcement on 28-08-2024
|
28 Aug 2024 | David Williams | Issued | 90,000 | $51,300 |
Placement.
|
28 Aug 2024 | David Williams | Issued | 180,000 | $90,000 |
Placement.
|
28 Aug 2024 | Philip (Phil) Powell | Issued | 60,000 | $30,000 |
Placement.
|
28 Aug 2024 | Philip (Phil) Powell | Issued | 30,000 | $17,100 |
Placement. As per announcement on 28-08-2024
|
28 Aug 2024 | Robert (Max) Johnston | Issued | 100,000 | $57,000 |
Placement. As per announcement on 28-08-2024
|
28 Aug 2024 | Robert (Max) Johnston | Issued | 200,000 | $100,000 |
Placement.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David Williams | Non-Executive ChairmanNon-Executive Director | Nov 2023 |
Mr Williams is an experienced Director and investment banker with a record in business development as well as in mergers and acquisitions and capital raising. He has experience advising ASX-listed companies in the food, medical device and pharmaceutical sectors. Mr Williams is currently Managing Director of corporate advisory firm Kidder Williams.
|
Mr Philip (Phil) John Powell | Non-Executive Director | Jun 2019 |
Mr Powell has experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other corporate finance assignments across a range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell is the Chair of the Risk Committee.
|
Mr Geoffrey A. Cumming | Non-Executive Director | Jul 2020 |
Mr Cumming has held roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the growing and profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was in designing and securing funding arrangements through a range of capital raising initiatives, including government grants, partnering and co-development deals. He was previously Chairman of Sienna Cancer Diagnostics Ltd. Dr Cumming is a member of the Risk Committee.
|
Mr Robert (Max) Maxwell Johnston | Non-Executive Director | Jun 2019 |
Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Self Medication Industry (ASMI). Mr Johnston has had overseas experience during his career in leading businesses in Western and Central-Eastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is a member of the Company's Risk Committee.
|
Ms Mary Harney | Non-Executive Director | Oct 2024 |
Ms Harney is a Non-Executive Director and Chief Executive and brings a understanding of applied life science research, in addition to experience in biopharmaceutical regulatory affairs and commercialisation. Ms Harney is the current Chair of Microbio Pty Ltd. She was previously the Chair of Race Oncology (ASX: RAC), a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care.
|
Dr Leearne Hinch | Chief Executive Officer | Nov 2016 |
-
|
Mr Mark Edwards | Chief Financial OfficerCompany Secretary | Nov 2022 |
-
|
Leearne Hinch | Chief Executive Officer |
-
|
|
Mark Edwards | Chief Financial OfficerCompany Secretary |
-
|
|
Gregory Rice | Chief Scientific Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
The Trust Company Australia Limited <Mof A/C> | 6,487,000 | 5.86% |
Fresh Start Australia Pty Ltd | 4,000,000 | 3.61% |
Dr Irmgard Irminger-Finger | 3,380,000 | 3.05% |
The Trust Company (Australia) Limited <Mbf A/C> | 3,139,333 | 2.83% |
Lawn Views Pty Ltd <Angela Williams Family A/C> | 2,676,924 | 2.42% |
Moggs Creek Pty Ltd <Moggs Creek Super A/C> | 2,389,747 | 2.16% |
Citicorp Nominees Pty Limited | 2,056,600 | 1.86% |
Lesamourai Pty Ltd | 2,000,000 | 1.81% |
J P Morgan Nominees Australia Pty Limited | 1,667,697 | 1.51% |
Mr Peter William Rogers and Ms Alida Johanna Clark <R&C Super Fund A/C> | 1,304,436 | 1.18% |
Supergun Pty Ltd <Bricklanding Super Fund A/C> | 1,160,000 | 1.05% |
Trovex Pty Ltd | 1,090,000 | 0.98% |
Mr Nathan Ryan Wagner | 1,010,562 | 0.91% |
Mr Adam Garrigan | 1,000,000 | 0.90% |
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 997,265 | 0.90% |
Mr Neil Donal Delroy <The Ndd Investment A/C> | 956,000 | 0.86% |
Traoj Pty Ltd <Traoj A/C> | 952,933 | 0.86% |
David Neate | 902,257 | 0.81% |
B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> | 660,000 | 0.60% |
UBS nominees Pty Ltd | 600,000 | 0.54% |